Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
116 hedge funds and large institutions have $1.18B invested in Kite Pharma, Inc. in 2014 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 39 increasing their positions, 8 reducing their positions, and 7 closing their positions.
814% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 7
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
388% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 8
355% more capital invested
Capital invested by funds: $260M → $1.18B (+$923M)
87% more funds holding
Funds holding: 62 → 116 (+54)
57% less call options, than puts
Call options by funds: $3.76M | Put options by funds: $8.64M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$61.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.1M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$30.7M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$30.5M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$23.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$36M |
| 2 |
VAM
Visium Asset Management
New York
|
-$8.46M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$5.7M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$2.79M |
| 5 |
DP
DSAM Partners
London,
United Kingdom
|
-$2.01M |
KITE Hedge Fund Activity: Q4 2014 in Review
116 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q4 2014, worth a combined $1.18B — up 355% from $260M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new KITE positions and 7 closed out — a net gain of 57 holders — while 39 added to existing stakes and 8 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $61.8M. The largest seller was Deerfield Management, cutting an estimated $36M.
- 116 institutional investors held Kite Pharma, Inc. (KITE) as of Q4 2014, up from 62 in Q3 2014.
- Funds reported $1.18B of Kite Pharma, Inc. stock for Q4 2014, up 355% quarter-over-quarter.
- 64 funds opened new Kite Pharma, Inc. positions in Q4 2014 and 7 closed out, a net change of +57 holders.
- The largest Kite Pharma, Inc. buyer in Q4 2014 was Capital Research Global Investors, an estimated $61.8M added.
- The largest Kite Pharma, Inc. seller in Q4 2014 was Deerfield Management, an estimated $36M sold.
Based on aggregated 13F filings for Q4 2014.